Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Mediators Inflamm. 2019 Oct 9;2019:9515346. doi: 10.1155/2019/9515346. eCollection 2019.
Interleukin-37 (IL-37) acts as an inhibitor of innate and adaptive immunity. However, the exact role of IL-37 in the patients with acute coronary syndrome (ACS) remains to be elucidated.
Patients were classified into 4 groups: normal coronary artery (NCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). The circulating Treg, Th1, and Th17 frequencies were measured. The effect of IL-37 on stimulated peripheral blood mononuclear cells (PBMCs) and the influence of IL-37 on DCs were explored. In addition, the role of IL-37-treated tDCs on Treg cell expansion and the stability of these tDCs were also tested.
Our results showed that the circulating Treg frequencies were decreased, while Th1 and Th17 frequencies were increased in ACS patients, and that IL-37 expanded Tregs but suppressed Th1 and Th17 cells in activated PBMCs derived from ACS patients. Of note, IL-37-treated human DCs obtained a tolerogenic phenotype, and such tDCs promoted expansion of Tregs and decreased the Th1 and Th17 populations when cocultured with CD4 T cells. Interestingly, IL-37-treated DCs from patients with ACS are phenotypically and functionally comparable to IL-37-treated DCs from NCA patients, and tolerogenic properties of IL-37-treated DCs were highly stable.
In conclusion, our results reveal a beneficial role of IL-37 in the patients with ACS and suggest that autologous IL-37-treated tDCs may be a novel therapeutic strategy for the patients with ACS.
白细胞介素-37（IL-37）作为先天和适应性免疫的抑制剂。然而，IL-37 在急性冠脉综合征（ACS）患者中的确切作用仍有待阐明。
患者被分为 4 组：正常冠状动脉（NCA）、稳定型心绞痛（SA）、不稳定型心绞痛（UA）和急性心肌梗死（AMI）。测量循环 Treg、Th1 和 Th17 的频率。探讨了 IL-37 对刺激外周血单核细胞（PBMC）的作用以及 IL-37 对 DC 的影响。此外，还测试了 IL-37 处理的 tDC 对 Treg 细胞扩增的作用以及这些 tDC 的稳定性。
我们的结果表明，ACS 患者的循环 Treg 频率降低，而 Th1 和 Th17 频率升高，IL-37 在 ACS 患者来源的激活 PBMC 中扩增 Treg，但抑制 Th1 和 Th17 细胞。值得注意的是，IL-37 处理的人 DC 获得了耐受性表型，并且当与 CD4 T 细胞共培养时，这些 tDC 促进了 Treg 的扩增并减少了 Th1 和 Th17 群体。有趣的是，ACS 患者的 IL-37 处理的 DC 在表型和功能上与 NCA 患者的 IL-37 处理的 DC 相当，并且 IL-37 处理的 DC 的耐受性非常稳定。
总之，我们的结果揭示了 IL-37 在 ACS 患者中的有益作用，并表明自体 IL-37 处理的 tDC 可能是 ACS 患者的一种新的治疗策略。
Zotero 插件
